Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.

ABSTRACT:

Background

The rising cost of cancer drug therapy threatens the long-term sustainability of Taiwan National Health Insurance. Cost savings can be achieved through various strategies, e.g., using smaller vial sizes, sharing vials, weight-based dosing, or switching to biosimilars. Here we aimed to examine the cost-effectiveness of a trastuzumab biosimilar combined with docetaxel (TDbiol) for treatment-naïve HER2⁺ metastatic breast cancer (MBC), and the financial impact of drug wastage.

Methods

A Markov model with three health states was developed to assess the cost-effectiveness of trastuzumab biosimilars plus docetaxel over a 40-month time horizon in patients with HER2⁺ MBC. Based on the literature and our expert opinion, we assumed similar efficacy betw

SUBMITTER: Leung JH 

PROVIDER: S-EPMC9305615 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature